![Robert Brenner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Brenner
Technik-/Wissenschafts-/F&E-Leiter bei
VERA THERAPEUTICS, INC.
Vermögen: 241 643 $ am 31.05.2026
Profil
Robert M.
Brenner is Chief Medical Officer at Vera Therapeutics, Inc. since 2023.
Formerly, Dr. Brenner was President & Chief Executive Officer at AlloCure, Inc. in 2010; Executive Director-Nephrology Medical Affairs at Amgen, Inc. from 1999 to 2008; Senior Vice President-Medical Affairs at AMAG Pharmaceuticals, Inc. from 2008 to 2010; Chief Medical Officer at Orionis Biosciences, Inc. from 2015 to 2018; and Executive VP-Research & Development at Codiak BioSciences, Inc. from 2018 to 2019.
Education includes undergraduate studies at The Johns Hopkins University and a doctorate from Albert Einstein College of Medicine, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.03.2026 | 6.803 ( 0,01 % ) | 241 643 $ | 31.05.2026 |
Aktive Positionen von Robert Brenner
| Unternehmen | Position | Beginn |
|---|---|---|
| VERA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 08.01.2023 |
Ehemalige bekannte Positionen von Robert Brenner
| Unternehmen | Position | Ende |
|---|---|---|
| CODIAK BIOSCIENCES | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2019 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2018 |
| AMAG PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 04.06.2010 |
| AMGEN INC. | Corporate Officer/Principal | 01.05.2008 |
AlloCure, Inc.
 AlloCure, Inc. BiotechnologyHealth Technology Develops cell therapies for the treatment of kidney diseases, organ transplants and multi-organ injuries | Vorstandsvorsitzender | 28.12.2010 |
Ausbildung von Robert Brenner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
79
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
AlloCure, Inc.
AlloCure, Inc. BiotechnologyHealth Technology Develops cell therapies for the treatment of kidney diseases, organ transplants and multi-organ injuries | Health Technology |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technology Services |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Wählen Sie MarketScreener 
